Rallybio announces data for RLYB11, extends runway to Q325

Rallybio announced preliminary Phase 1 multiple ascending dose or MAD, data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 C5 , in development for patients with complement-mediated diseases. “The preliminary results from this Phase 1 multiple ascending dose study of RLYB116 support continued development in patients with gMG,” said Eric Watsky, M.D., RLYB116 Program Lead for Rallybio. “We are encouraged by the free C5 reductions demonstrated by RLYB116 as well as the exposures achieved with subcutaneous administration…The Company is also updating its cash runway guidance and now expects its current cash, cash equivalents and marketable securities to extend the runway into the third quarter of 2025. “We are pleased to see substantial reductions in free C5 with once weekly subcutaneous dosing of RLYB116,” said Stephen Uden, M.D., Chief Executive Officer of Rallybio. “The Phase 1 MAD data show us that RLYB116 can be a potential therapeutic to treat gMG and other complement mediated diseases. In the spirit of managing our cash runway to realize the most value from our portfolio, we have decided to focus our RLYB116 investments on the manufacturing process with a goal of expanding the scope of therapeutic indications and addressing unmet medical need. In parallel, we continue to advance our lead program, RLYB212, and have extended our runway into the third quarter of 2025.”